The influence of multiple oral administration on the pharmacokinetics and distribution profile of dalcetrapib in rats

被引:1
作者
Takubo, Hiroaki [1 ]
Ishikawa, Tomohiro [1 ]
Taniguchi, Toshio [1 ]
Iwanaga, Kazunori [2 ]
Nomura, Yukihiro [1 ]
机构
[1] Japan Tobacco Inc, Cent Pharmaceut Res Inst, Drug Metab & Pharmacokinet Res Labs, 1-1 Murasakicho, Takatsuki, Osaka 5691125, Japan
[2] Osaka Univ Pharmaceut Sci, Educ & Res Ctr Clin Pharm, Osaka, Japan
关键词
Dalcetrapib; JTT-705; RO4607381; pharmacokinetics; covalent binding; mixed disulfide; CETP; INTESTINAL LYMPHATIC TRANSPORT; COVALENT BINDING; C-14; CAPTOPRIL; ABSORPTION; DISPOSITION; METABOLISM; VEHICLES; CYSTEINE; SINGLE;
D O I
10.1080/00498254.2020.1809030
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We investigated the influence of multiple oral administration on the accumulation of dalcetrapib (JTT-705/RO4607381), a novel cholesteryl ester transfer protein inhibitor, in rats. It is well known that orally administered dalcetrapib is rapidly hydrolysed to its active form, which has a sulfhydryl group, in the body. The active form then binds covalently to endogenous thiols via mixed disulfide bonds. Following multiple once daily oral administration of(14)C-dalcetrapib for seven days to rats, the concentration of radioactivity in the plasma and almost all tissues reached the steady state by day 4. At 24 h after the last dose, there was a relatively high concentration of radioactivity in the mesenteric lymph nodes, liver, adrenal glands and fat. After the last dose to rats, the radioactivity was almost completely recovered in the urine and faeces, indicating that dalcetrapib is not retained in the body, probably due to the reversibility of the disulfide bonds despite being covalent bonds.
引用
收藏
页码:82 / 87
页数:6
相关论文
共 21 条
[1]   Interaction of the active metabolite of prasugrel, R-138727, with cysteine 97 and cysteine 175 of the human P2Y12 receptor [J].
Algaier, I. ;
Jakubowski, J. A. ;
Asai, F. ;
Von Kuegelgen, I. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2008, 6 (11) :1908-1914
[2]   Targeted Covalent Inhibitors for Drug Design [J].
Baillie, Thomas A. .
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2016, 55 (43) :13408-13421
[3]   Evidence of a Drug-Drug Interaction Linked to Inhibition of Ester Hydrolysis by Orlistat [J].
Bentley, Darren ;
Young, Anne-Marie ;
Rowell, Lucy ;
Gross, Guenter ;
Tardio, Joseph ;
Carlile, David .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2012, 60 (04) :390-396
[4]   Can N-acetylcysteine reverse the antiplatelet effects of clopidogrel?: An in vivo and vitro study [J].
Campbell, CL ;
Berger, PB ;
Nuttall, GA ;
Orford, JL ;
Santrach, PJ ;
Oliver, WC ;
Ereth, MH ;
Thompson, CM ;
Murphy, MK ;
McGlassen, DL ;
Schrader, LM ;
Steinhubl, SR .
AMERICAN HEART JOURNAL, 2005, 150 (04) :796-799
[5]   ESTIMATING THE MAXIMAL POTENTIAL FOR INTESTINAL LYMPHATIC TRANSPORT OF LIPOPHILIC DRUG MOLECULES [J].
CHARMAN, WNA ;
STELLA, VJ .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1986, 34 (1-2) :175-178
[6]   STUDIES ON THIOL AND DISULFIDE COMPOUNDS .1. ABSORPTION DISTRIBUTION METABOLISM AND EXCRETION OF S-35-2-MERCAPTOPROPIONYLGLYCINE [J].
CHIBA, T ;
KITOO, H ;
TOSHIOKA, N .
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 1973, 93 (01) :112-118
[7]  
Derks M, 2010, CLIN PHARMACOL THER, V87, pS24
[8]  
Derks M, 2011, CLIN DRUG INVEST, V31, P325, DOI 10.2165/11533550-000000000-00000
[9]   A Single-Center, Open-Label, One-Sequence Study of Dalcetrapib Coadministered With Ketoconazole, and an In Vitro Study of the S-Methyl Metabolite of Dalcetrapib [J].
Derks, Michael ;
Fowler, Stephen ;
Kuhlmann, Olaf .
CLINICAL THERAPEUTICS, 2009, 31 (03) :586-599
[10]   Solubility and stability of dalcetrapib in vehicles and biological media [J].
Gross, Guenter ;
Tardio, Joseph ;
Kuhlmann, Olaf .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2012, 437 (1-2) :103-109